TRAIL receptors are known transcriptional targets of the tumor suppressor protein p53, and chemotherapeutic agents potentiate cell death in wild-type p53-expressing tumor cells by enhancing TRAIL-R1/R2 expression at the plasma membrane [14,15]. The gene discussed is TP53; the disease is neoplasm.